A citation-based method for searching scientific literature

Nicole A Sherry, Wei Chen, Jake A Kushner, Mariela Glandt, Qizhi Tang, Sue Tsai, Pere Santamaria, Jeffrey A Bluestone, Anne-Marie B Brillantes, Kevan C Herold. Endocrinology 2007
Times Cited: 138







List of co-cited articles
994 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
Bart Keymeulen, Evy Vandemeulebroucke, Anette G Ziegler, Chantal Mathieu, Leonard Kaufman, Geoff Hale, Frans Gorus, Michel Goldman, Markus Walter, Sophie Candon,[...]. N Engl J Med 2005
785
41

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
Kevan C Herold, William Hagopian, Julie A Auger, Ena Poumian-Ruiz, Lesley Taylor, David Donaldson, Stephen E Gitelman, David M Harlan, Danlin Xu, Robert A Zivin,[...]. N Engl J Med 2002
837
38

Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.
L Chatenoud, E Thervet, J Primo, J F Bach. Proc Natl Acad Sci U S A 1994
499
28

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.
Kevan C Herold, Stephen E Gitelman, Umesh Masharani, William Hagopian, Brygida Bisikirska, David Donaldson, Kristina Rother, Beverly Diamond, David M Harlan, Jeffrey A Bluestone. Diabetes 2005
459
28

Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4.
Norihiko Ogawa, James F List, Joel F Habener, Takashi Maki. Diabetes 2004
127
27

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Nicole Sherry, William Hagopian, Johnny Ludvigsson, Sunil M Jain, Jack Wahlen, Robert J Ferry, Bruce Bode, Stephen Aronoff, Christopher Holland, David Carlin,[...]. Lancet 2011
290
25

TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes.
Mériam Belghith, Jeffrey A Bluestone, Samia Barriot, Jérôme Mégret, Jean-François Bach, Lucienne Chatenoud. Nat Med 2003
478
24

Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs.
Damien Bresson, Lisa Togher, Evelyn Rodrigo, Yali Chen, Jeffrey A Bluestone, Kevan C Herold, Matthias von Herrath. J Clin Invest 2006
234
24

Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.
Mark D Pescovitz, Carla J Greenbaum, Heidi Krause-Steinrauf, Dorothy J Becker, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Jennifer B Marks, Paula F McGee, Antoinette M Moran,[...]. N Engl J Med 2009
629
24


Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.
B Keymeulen, M Walter, C Mathieu, L Kaufman, F Gorus, R Hilbrands, E Vandemeulebroucke, U Van de Velde, L Crenier, C De Block,[...]. Diabetologia 2010
211
21

Exendin-4 modulates diabetes onset in nonobese diabetic mice.
Irene Hadjiyanni, Laurie L Baggio, Philippe Poussier, Daniel J Drucker. Endocrinology 2008
79
25

GAD treatment and insulin secretion in recent-onset type 1 diabetes.
Johnny Ludvigsson, Maria Faresjö, Maria Hjorth, Stina Axelsson, Mikael Chéramy, Mikael Pihl, Outi Vaarala, Gun Forsander, Sten Ivarsson, Calle Johansson,[...]. N Engl J Med 2008
332
20

Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation.
Vitaly Ablamunits, Octavian Henegariu, Jakob Bondo Hansen, Lynn Opare-Addo, Paula Preston-Hurlburt, Pere Santamaria, Thomas Mandrup-Poulsen, Kevan C Herold. Diabetes 2012
88
22

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.
Tihamer Orban, Brian Bundy, Dorothy J Becker, Linda A DiMeglio, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Carla J Greenbaum, Jennifer B Marks, Roshanak Monzavi,[...]. Lancet 2011
347
19

Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice.
Wilma L Suarez-Pinzon, Robert F Power, Yanhua Yan, Clive Wasserfall, Mark Atkinson, Alex Rabinovitch. Diabetes 2008
132
16

Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice.
Chang-yun Hu, Daniel Rodriguez-Pinto, Wei Du, Anupama Ahuja, Octavian Henegariu, F Susan Wong, Mark J Shlomchik, Li Wen. J Clin Invest 2007
295
16

Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study.
Lucy Mastrandrea, Jihnhee Yu, Torsten Behrens, John Buchlis, Christine Albini, Shannon Fourtner, Teresa Quattrin. Diabetes Care 2009
143
16

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
Kevan C Herold, Stephen E Gitelman, Mario R Ehlers, Peter A Gottlieb, Carla J Greenbaum, William Hagopian, Karen D Boyle, Lynette Keyes-Elstein, Sudeepta Aggarwal, Deborah Phippard,[...]. Diabetes 2013
185
15


Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor.
Lei Tian, Jie Gao, Jianqiang Hao, Yu Zhang, Huimin Yi, Timothy D O'Brien, Robert Sorenson, Jian Luo, Zhiguang Guo. Endocrinology 2010
86
16

Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes.
Nicole A Sherry, Jake A Kushner, Mariela Glandt, Tadahiro Kitamura, Anne-Marie B Brillantes, Kevan C Herold. Diabetes 2006
118
13

CD3-specific antibodies: a portal to the treatment of autoimmunity.
Lucienne Chatenoud, Jeffrey A Bluestone. Nat Rev Immunol 2007
258
13

C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.
Carlos E B Couri, Maria C B Oliveira, Ana B P L Stracieri, Daniela A Moraes, Fabiano Pieroni, George M N Barros, Maria Isabel A Madeira, Kelen C R Malmegrim, Maria C Foss-Freitas, Belinda P Simões,[...]. JAMA 2009
266
13

Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.
Kristina I Rother, Lisa M Spain, Robert A Wesley, Benigno J Digon, Alain Baron, Kim Chen, Patric Nelson, H-Michael Dosch, Jerry P Palmer, Barbara Brooks-Worrell,[...]. Diabetes Care 2009
95
13



B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions.
Yan Xiu, Carmen P Wong, Jean-David Bouaziz, Yasuhito Hamaguchi, Yaming Wang, Shannon M Pop, Roland M Tisch, Thomas F Tedder. J Immunol 2008
158
12


Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation.
Greg Simon, Matthew Parker, Vijayakumar Ramiya, Clive Wasserfall, Yanfei Huang, Damien Bresson, R Fletcher Schwartz, Martha Campbell-Thompson, Lauren Tenace, Todd Brusko,[...]. Diabetes 2008
57
21

Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice.
Matthew J Parker, Song Xue, John J Alexander, Clive H Wasserfall, Martha L Campbell-Thompson, Manuela Battaglia, Silvia Gregori, Clayton E Mathews, Sihong Song, Misty Troutt,[...]. Diabetes 2009
57
21

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
Kevan C Herold, Stephen Gitelman, Carla Greenbaum, Jennifer Puck, William Hagopian, Peter Gottlieb, Peter Sayre, Peter Bianchine, Emelita Wong, Vicki Seyfert-Margolis,[...]. Clin Immunol 2009
133
12

Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.
Júlio C Voltarelli, Carlos E B Couri, Ana B P L Stracieri, Maria C Oliveira, Daniela A Moraes, Fabiano Pieroni, Marina Coutinho, Kelen C R Malmegrim, Maria C Foss-Freitas, Belinda P Simões,[...]. JAMA 2007
354
11

Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.
Jay S Skyler, Jeffrey P Krischer, Joseph Wolfsdorf, Catherine Cowie, Jerry P Palmer, Carla Greenbaum, David Cuthbertson, Lisa E Rafkin-Mervis, H Peter Chase, Ellen Leschek. Diabetes Care 2005
385
11

Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes.
Zandong Yang, Meng Chen, Jeffrey D Carter, Craig S Nunemaker, James C Garmey, Sarah D Kimble, Jerry L Nadler. Biochem Biophys Res Commun 2006
40
25

Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes.
J Zhang, Y Tokui, K Yamagata, J Kozawa, K Sayama, H Iwahashi, K Okita, M Miuchi, H Konya, T Hamaguchi,[...]. Diabetologia 2007
55
18

Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus.
J Silverstein, N Maclaren, W Riley, R Spillar, D Radjenovic, S Johnson. N Engl J Med 1988
234
10

Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment.
Sylvaine You, Bertrand Leforban, Corinne Garcia, Jean-François Bach, Jeffrey A Bluestone, Lucienne Chatenoud. Proc Natl Acad Sci U S A 2007
137
10


Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset.
C R Stiller, J Dupré, M Gent, M R Jenner, P A Keown, A Laupacis, R Martell, N W Rodger, B von Graffenried, B M Wolfe. Science 1984
625
10

Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.
Michael W Steffes, Shalamar Sibley, Melissa Jackson, William Thomas. Diabetes Care 2003
450
10

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
J Andrew Pospisilik, Jennifer Martin, Timothy Doty, Jan A Ehses, Nathalie Pamir, Francis C Lynn, Shalea Piteau, Hans-Ulrich Demuth, Christopher H S McIntosh, Raymond A Pederson. Diabetes 2003
271
10

Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction.
Qizhi Tang, Jason Y Adams, Cristina Penaranda, Kristin Melli, Eliane Piaggio, Evridiki Sgouroudis, Ciriaco A Piccirillo, Benoit L Salomon, Jeffrey A Bluestone. Immunity 2008
540
10

In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes.
Qizhi Tang, Kammi J Henriksen, Mingying Bi, Erik B Finger, Greg Szot, Jianqin Ye, Emma L Masteller, Hugh McDevitt, Mark Bonyhadi, Jeffrey A Bluestone. J Exp Med 2004
876
10

The NOD mouse: a model of immune dysregulation.
Mark S Anderson, Jeffrey A Bluestone. Annu Rev Immunol 2005
756
10

Type 1 diabetes: etiology, immunology, and therapeutic strategies.
Tom L van Belle, Ken T Coppieters, Matthias G von Herrath. Physiol Rev 2011
569
10

IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells.
Yenkel Grinberg-Bleyer, Audrey Baeyens, Sylvaine You, Rima Elhage, Gwladys Fourcade, Sylvie Gregoire, Nicolas Cagnard, Wassila Carpentier, Qizhi Tang, Jeffrey Bluestone,[...]. J Exp Med 2010
277
10

Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.
Kirsti Näntö-Salonen, Antti Kupila, Satu Simell, Heli Siljander, Tiina Salonsaari, Anne Hekkala, Sari Korhonen, Risto Erkkola, Jukka I Sipilä, Lotta Haavisto,[...]. Lancet 2008
241
9


No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.
Markus Walter, Areti Philotheou, François Bonnici, Anette-G Ziegler, Roland Jimenez. Diabetes Care 2009
79
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.